Pilot Trial Investigating the Role of Circulating Tumor DNA as a Risk Stratification Tool to Guide Adjuvant Therapy in Endometrial Cancer
Deaths from uterine cancer (including endometrial cancer) are increasing across the United States. There is a lack of clear guidance on which patients should get what treatment. We are investigating a blood test to help identify women with endometrial cancer who should get chemotherapy, radiation therapy, or a combination of both. This blood test examines the DNA from endometrial cancer that is in the blood as well as the mutations in the endometrial cancer’s DNA. We will first run a pilot clinical trial to determine if this test can detect endometrial cancer DNA, then determine if this DNA and its mutations are associated with how women with endometrial cancer respond to treatment. We hope this blood test will be able to personalize treatments for women with endometrial cancer and improve survival.
